Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction

MLA

“Finerenone Meets Primary Endpoint in Phase III FINEARTS-HF Cardiovascular Outcomes Study in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.” European Union News, 6 Aug. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.804291881&authtype=sso&custid=ns315887.

APA

Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction. (2024, August 6). European Union News.

Chicago

European Union News. 2024. “Finerenone Meets Primary Endpoint in Phase III FINEARTS-HF Cardiovascular Outcomes Study in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction,” August 6. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.804291881&authtype=sso&custid=ns315887.